纤维肌痛程度与类风湿关节炎患者糖皮质激素持续使用的关系
本研究随访97例接受口服泼尼松的活动性RA患者,在启动新DMARD后约3个月评估纤维肌痛程度(FSQ)与糖皮质激素持续使用的关联。校正炎症活动等因素后,高/极高纤维肌痛与泼尼松持续使用相关(OR 4.99,95%CI 1.20,20.73)。
要点
- 高纤维肌痛程度与RA患者3个月时泼尼松持续使用相关,且独立于炎症活动。
- 纤维肌痛评估或有助于识别糖皮质激素难以减停的RA患者。
核心结论
- 高纤维肌痛程度与RA患者糖皮质激素持续使用相关,独立于炎症活动。
研究设计与样本
- 随访接受口服泼尼松的活动性RA患者,在启动新DMARD后约3个月观察,共97例基线使用泼尼松。
- 纤维肌痛程度用纤维肌痛调查问卷(FSQ)测量,分为低(<8)、中(8-10)、高/极高(>10)。
- 采用多重逻辑回归校正基线人口学、RA病程、血清学状态及以肿胀关节数和CRP评估的炎症活动。
主要发现
- 基线使用泼尼松的97例中,65%在随访时仍在服用泼尼松。
- 校正非炎症因素与炎症活动后,高/极高纤维肌痛者随访时服用泼尼松的可能性高于低纤维肌痛者(OR 4.99,95%CI 1.20,20.73)。
关键数值与推荐
- FSQ分层:<8为低,8-10为中度,>10为高/极高。
- 糖皮质激素持续使用定义为DMARD启动后3个月随访时仍使用泼尼松。
- 高/极高纤维肌痛与泼尼松持续使用的校正OR为4.99(95%CI 1.20,20.73)。
临床怎么用
- 对RA患者评估纤维肌痛程度,可能有助于预判糖皮质激素减停难度。
- 糖皮质激素持续使用不应仅归因于炎症活动,需关注非炎症性疼痛因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Over one-third of patients with RA exhibit evidence of fibromyalgianess, which is associated with higher rates of disability and inadequate responsiveness to RA treatment. Patients with RA often remain on glucocorticoids long-term, despite the known risk of dose-dependent morbidity. We undertook this study to examine the relationship between fibromyalgianess and glucocorticoid persistence among RA patients. METHODS: We followed participants with active RA on oral prednisone for ∼3 months after initiating a new DMARD. Fibromyalgianess was measured using the Fibromyalgia Survey Questionnaire (FSQ), previously shown to correlate with key FM features often superimposed upon RA. Severity of fibromyalgianess was stratified as follows: FSQ <8 low, FSQ 8-10 moderate and FSQ >10 high/very high. The association between baseline fibromyalgianess and glucocorticoid persistence, defined as prednisone use at 3-month follow-up visit after DMARD initiation, was assessed using multiple logistic regression adjusted for baseline demographics, RA duration, serostatus and inflammatory activity assessed using swollen joint count and CRP. RESULTS: Of the 97 participants on prednisone at baseline, 65% were still taking prednisone at follow-up. Fifty-seven percent of participants with low baseline fibromyalgianess had persistent glucocorticoid use, compared with 84% of participants with high or very high fibromyalgianess. After adjustment for non-inflammatory factors and inflammatory activity, participants with high/very high baseline fibromyalgianess were more likely to be taking prednisone at follow-up relative to those with low fibromyalgianess [odds ratio 4.99 (95% CI 1.20, 20.73)]. CONCLUSION: High fibromyalgianess is associated with persistent glucocorticoid use, independent of inflammatory activity.
引用
- Wallace BI, Moore MN, Heisler AC, et al. Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34293092. doi:10.1093/rheumatology/keab583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。